Find a company
Owlstone is developing a non-invasive screening device for early stage lung cancer utilizing breath diagnostics. As for most cancers, early diagnosis of lung cancer leads to better patient outcomes. The LuCID (Lung Cancer Indicator Detection) project will allow Owlstone’s existing chemical detection technology to be used to diagnose lung cancer, by measuring the trace chemicals present in the breath of lung cancer patients.
| Project | Non-invasive Screening Device for Early Stage Lung Cancer |
|---|---|
| Description |
Owlstone is developing a non-invasive screening device for early stage lung cancer utilizing breath diagnostics. As for most cancers, early diagnosis of lung cancer leads to better patient outcomes. The LuCID (Lung Cancer Indicator Detection) project will allow Owlstone’s existing chemical detection technology to be used to diagnose lung cancer, by measuring the trace chemicals present in the breath of lung cancer patients. |
| Funding | £ 912,310 |
| Competition | Competition 5 - Improving Diagnosis and Treatment Management of Cancer |
| Competition Date | September 2013 |
| Health Innovation Network Partner | Health Innovation East |
| Website | http://www.owlstonenanotech.com/ |